Pharmalot

By  Ed Silverman

Taking stock of the drug industry, from the lab to the medicine chest. Sign up for the newsletter here.

Bernie Sanders
Pharmalot

Sanders accuses a drug maker of ‘immoral exploitation’ for the price of a rare disease drug

By Ed Silverman

Pharmalot

Pharmalittle: Will wholesalers get pulled into a price-fixing case? FDA rejects Alkermes depression drug

By Ed Silverman

Vertex
Pharmalot

U.K. lawmaker challenges the government to issue a compulsory license for Vertex drug

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Azar formally proposes curbing rebates; ‘easy money’ from Insys led to lots of prescriptions

By Ed Silverman

DEA Prescription Drug
Pharmalot

European Commission argues pharma deserves further antitrust scrutiny

By Ed Silverman

Herceptin
Pharmalot

Swiss government is asked to issue a compulsory license for a Roche cancer drug

By Ed Silverman

Pharmalot

Pharmalittle: A ‘one-off opportunity’ to raise valsartan price by 469 percent; Takeda’s risky road for dengue vaccine

By Ed Silverman

FDA Drug Labels
Pharmalot

Many doctors are uncertain about the FDA approval process — and don’t like off-label marketing

By Ed Silverman

Pharmalot

Pharmalittle: Roche halts Alzheimer’s drug trials; is public health jeopardized as FDA fast tracks generics?

By Ed Silverman

Pills price rebate
Pharmalot

Drug prices are forecast to grow slowly over the next five years, but some will still feel pain

By Ed Silverman

Marylou Sudders
Pharmalot

Here’s how Massachusetts officials hope to lower their Medicaid drug spending

By Ed Silverman

Pharmalot

Pharmalittle: Congressional hearings on drug pricing begin; Indian panel recommends compulsory licenses

By Ed Silverman

Jeffrey Leiden
Pharmalot

Vertex faces more pressure over pricing, but one analyst does not expect any movement

By Ed Silverman

Pharmalot

AstraZeneca strikes a ‘novel’ deal with a Medicare plan to lower patient out-of-pocket costs

By Ed Silverman

Pharmalot

Pharmalittle: Insys execs go to trial for racketeering; CVS gives Amgen a headache in the migraine market

By Ed Silverman

Kings College London
Pharmalot

U.K. committee warns universities over failures to report clinical trials

By Ed Silverman

Hoarding Opioids
Pharmalot

Walgreens shareholders want to know how the retailer manages opioid risks

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Massachusetts seeks to negotiate directly with pharma; Civica looks to make 20 generics

By Ed Silverman

Pharmacy shelves
Pharmalot

Pharmacy benefit managers marked up generic drugs for NY Medicaid, but where’d the money go?

By Ed Silverman

Pharmalot

Whistleblower strikes back at Justice Department move to dismiss nurse educator lawsuits

By Ed Silverman

Walgreens
Pharmalot

An ‘instransigent’ Walgreens faces a shareholder proposal over managing opioid risks

By Ed Silverman

Pharmalot

Pharmalittle: Vertex CFO leaves due to ‘personal behavior’; EMA deals blow to Lilly cancer drug

By Ed Silverman

Pharmalot

The World Health Organization says cancer drug prices are ‘impairing’ access to treatment

By Ed Silverman

Drug Price Ad
Pharmalot

Trump plan to force drug makers to advertise prices might work, but not if pharma gets its way

By Ed Silverman

Pharmalot

Pharmalittle: J&J and Walgreens settle claims; Sun Pharma takes steps to appease anxious investors

By Ed Silverman

WALGREENS
Pharmalot

Walgreens pays $269 million to settle charges of overbilling government health programs

By Ed Silverman

Pharmalot
Pharmalot

Sun Pharma asks regulators to probe media over whistleblower allegations

By Ed Silverman

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy